RecruitingPhase 4NCT07609914

A Study to Learn About the Safety of Taking an Additional Dose of the Medicine Rimegepant in Adults With Migraine

A PHASE 4, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND EFFECTIVENESS OF REDOSING OF RIMEGEPANT IN PARTICIPANTS 18 YEARS OF AGE OR OLDER FOR THE ACUTE TREATMENT OF MIGRAINE


Sponsor

Pfizer

Enrollment

400 participants

Start Date

May 28, 2026

Study Type

INTERVENTIONAL

Conditions

Summary

Acute treatments for migraine may not provide sufficient pain relief after an initial dose, and a second dose of a given medication may be needed to fully abort an attack. International Headache Society (IHS) global practice recommendations for the Acute Treatment of Migraine suggest a second dose of the same medication within the recommended dose limit in people with headache relapse after successful initial treatment of a migraine attack. The primary purpose of this study is to evaluate the safety and tolerability of redosing of rimegepant when taken for the acute treatment of a migraine attack, as it is possible that some patients may benefit from a second dose of rimegepant in this setting.


Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Rimegepant for people with acute treatment of migraine. The study is currently recruiting participants at 7 locations.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGRimegepant

Rimegepant


Locations(11)

Hope Clinical Research

Canoga Park, California, United States

Neurology Offices of South Florida

Boca Raton, Florida, United States

Brainstorm Research

Miami, Florida, United States

Clinical Neuroscience Solutions

Orlando, Florida, United States

New England Regional Headache Center

Worcester, Massachusetts, United States

Michigan Headache & Neurological Institute

Ann Arbor, Michigan, United States

Proven Endpoints, LLC

Ridgeland, Mississippi, United States

Headache Wellness Center

Greensboro, North Carolina, United States

FutureSearch Trials of Neurology

Austin, Texas, United States

FutureSearch Trials of Dallas

Dallas, Texas, United States

MedStar Health - Department of Neurology

McLean, Virginia, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07609914


Related Trials